The more research I do, the more I agree with SI and the Mesoblast team that want to undertake a subsequent COVID-19 ARDS trial using Remestemcel-L ... look at what the daily death toll average has crept up to as at 11 January - 1.736 people dying each day on average in the USA alone
https://www.nytimes.com/
![]()
We are now more than 2 years into this pandemic and the number of people still dying each day is ridiculous IMO ..... many are happy to tout that the current regime of approved drugs and treatments have it all under control .... Really ? Far from it me thinks ...
Are Mesoblast Waiting on the 12 month data in support of the funding request ? The last patient was dosed around the 18th December, 2021 so final assessments would be being tidied up from the last few patients treated by now assuming they survived ....
![]()
Both the full 6 month and 12 month data should then be due soon IMO ....
https://www.clinicaltrials.gov/ct2/...atory Distress Syndrome&draw=2&rank=1
MSCs in COVID-19 ARDS
39. Pulmonary symptoms [ Time Frame: 6 months ]
including the presence of emphysema, COPD, asthma, pulmonary fibrosis, other pulmonary disease, and the need for respiratory support will be reported by randomization
40. Pulmonary symptoms [ Time Frame: 12 months ]
including the presence of emphysema, COPD, asthma, pulmonary fibrosis, other pulmonary disease, and the need for respiratory support will be reported by randomization
- Forums
- ASX - By Stock
- MSB
- RWE for 2nd MSB COVID-19 ARDS P3 Trial
RWE for 2nd MSB COVID-19 ARDS P3 Trial, page-74
-
- There are more pages in this discussion • 832 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
$1.17 |
Change
-0.025(2.10%) |
Mkt cap ! $1.330B |
Open | High | Low | Value | Volume |
$1.18 | $1.22 | $1.15 | $6.344M | 5.404M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 8683 | $1.16 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.17 | 32999 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 8683 | 1.155 |
7 | 295447 | 1.150 |
3 | 70786 | 1.145 |
6 | 196386 | 1.140 |
3 | 75486 | 1.135 |
Price($) | Vol. | No. |
---|---|---|
1.165 | 32999 | 1 |
1.170 | 62618 | 6 |
1.175 | 48590 | 3 |
1.180 | 79079 | 4 |
1.185 | 17090 | 2 |
Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online